ME02171B - Spoj za inhibiciju notch signalnog puta - Google Patents
Spoj za inhibiciju notch signalnog putaInfo
- Publication number
- ME02171B ME02171B MEP-2015-105A MEP2015105A ME02171B ME 02171 B ME02171 B ME 02171B ME P2015105 A MEP2015105 A ME P2015105A ME 02171 B ME02171 B ME 02171B
- Authority
- ME
- Montenegro
- Prior art keywords
- cancer
- pharmaceutically acceptable
- hydrate
- acceptable salt
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 10
- 102000005650 Notch Receptors Human genes 0.000 title 1
- 108010070047 Notch Receptors Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000037361 pathway Effects 0.000 title 1
- 230000011664 signaling Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 6
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 2
- 208000036566 Erythroleukaemia Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Claims (7)
1.Spoj, naznačen time što je spoj strukture:,ili njegova farmaceutski prihvatljiva sol ili hidrat.
2.Spoj, naznačen time što je spoj strukture: , ili njegova farmaceutski prihvatljiva sol.
3.Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s patentnim zahtjevom 1, ili njegovu farmaceutski prihvatljivu sol ili hidrat, uz farmaceutski prihvatljivu podlogu.
4.Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol ili hidrat, naznačen time što je namijenjen upotrebi u terapiji.
5.Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol ili hidrat, naznačen time što je namijenjen upotrebi u liječenju raka koji je akutna limfoblastična leukemija T-stanica, akutna limfoblastična leukemija, akutna mijelogena leukemija, kronična mijelogena leukemija, eritroleukemija, rak dojke, rak jajnika, melanom, rak pluća, rak gušterače, glioblastom, kolorektalni rak, rak glave i vrata, rak vrata maternice, rak prostate, rak jetre, karcinom pločastih stanica (usta), rak kože ili meduloblastom.
6.Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol ili hidrat, naznačen time što je namijenjen upotrebi u liječenju raka koji je akutna limfoblastična leukemija T-stanica, kronična mijelogena leukemija, eritroleukemija, rak dojke, rak jajnika, melanom, rak gušterače, glioblastom ili kolorektalni rak.
7.Spoj u skladu s patentnim zahtjevom 1, koji je kristalni hidrat, naznačen time što ima karakteristični uzorak difrakcije rendgenskih zraka na prahu, uz upotrebu zračenja CuKα, sa signalom na 22,97 ± 0,2 °2θ, u kombinaciji s jednim ili više signala na 11,96 ± 0,2, 18,81 ± 0,2, 20,78 60,2 ili 21,07 ± 0,2 °2θ na temperaturi i uz relativnu vlažnost okoliša
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161512016P | 2011-07-27 | 2011-07-27 | |
| US201161560486P | 2011-11-16 | 2011-11-16 | |
| EP12741192.4A EP2736920B1 (en) | 2011-07-27 | 2012-07-18 | Notch pathway signaling inhibitor compound |
| PCT/US2012/047100 WO2013016081A1 (en) | 2011-07-27 | 2012-07-18 | Notch pathway signaling inhibitor compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02171B true ME02171B (me) | 2015-10-20 |
Family
ID=46598983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-105A ME02171B (me) | 2011-07-27 | 2012-07-18 | Spoj za inhibiciju notch signalnog puta |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US8569286B2 (me) |
| EP (1) | EP2736920B1 (me) |
| JP (1) | JP6027110B2 (me) |
| KR (1) | KR101578309B1 (me) |
| CN (1) | CN103732612B (me) |
| AP (1) | AP4080A (me) |
| AR (1) | AR087107A1 (me) |
| AU (1) | AU2012287251B2 (me) |
| BR (1) | BR112014001600B1 (me) |
| CA (1) | CA2841178C (me) |
| CL (1) | CL2014000175A1 (me) |
| CO (1) | CO6862159A2 (me) |
| CR (1) | CR20140036A (me) |
| CY (1) | CY1116645T1 (me) |
| DK (1) | DK2736920T3 (me) |
| DO (1) | DOP2014000011A (me) |
| EA (1) | EA023044B1 (me) |
| EC (1) | ECSP14013179A (me) |
| ES (1) | ES2544937T3 (me) |
| GT (1) | GT201400012A (me) |
| HR (1) | HRP20150771T1 (me) |
| HU (1) | HUE027534T2 (me) |
| IL (1) | IL229988A (me) |
| JO (1) | JO3148B1 (me) |
| MA (1) | MA35611B1 (me) |
| ME (1) | ME02171B (me) |
| MX (1) | MX356536B (me) |
| MY (1) | MY184303A (me) |
| PE (1) | PE20141061A1 (me) |
| PH (1) | PH12014500215B1 (me) |
| PL (1) | PL2736920T3 (me) |
| PT (1) | PT2736920E (me) |
| RS (1) | RS54135B1 (me) |
| SI (1) | SI2736920T1 (me) |
| TW (1) | TWI568730B (me) |
| WO (1) | WO2013016081A1 (me) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10350216B2 (en) | 2013-01-14 | 2019-07-16 | The Trustees Of Columbia University In The City Of New York | Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders |
| CA2938626A1 (en) | 2013-07-26 | 2015-01-29 | John Rothman | Compositions to improve the therapeutic benefit of bisantrene |
| TWI704151B (zh) | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| JO3491B1 (ar) | 2015-07-07 | 2020-07-05 | Audion Therapeutics | مركبات مثبطة لإشارات مسار notch |
| IL287136B2 (en) | 2016-02-05 | 2023-09-01 | Denali Therapeutics Inc | Receptor inhibitors - interacting with protein kinase 1 |
| CN120661674A (zh) | 2016-03-15 | 2025-09-19 | 奥莱松基因组股份有限公司 | 用于治疗实体瘤的lsd1抑制剂的组合 |
| AU2017249078B2 (en) * | 2016-04-12 | 2022-10-20 | Eli Lilly And Company | Combination therapy with notch and CDK4/6 inhibitors for the treatment of cancer |
| MX380780B (es) * | 2016-04-12 | 2025-03-12 | Lilly Co Eli | TERAPIA COMBINATORIA CON INHIBIDORES NOTCH Y PI3K/mTOR. |
| US10688104B2 (en) | 2016-05-20 | 2020-06-23 | Eli Lilly And Company | Combination therapy with Notch and PD-1 or PD-L1 inhibitors |
| CN109562114A (zh) * | 2016-08-31 | 2019-04-02 | 伊莱利利公司 | 用于治疗实体瘤的给药方案 |
| CA3039405A1 (en) | 2016-10-12 | 2018-04-19 | Eli Lilly And Company | Targeted treatment of mature t-cell lymphoma |
| HUE058802T2 (hu) | 2016-12-09 | 2022-09-28 | Denali Therapeutics Inc | RIPK1 inhibitorokként alkalmas vegyületek |
| CN110461335A (zh) | 2017-02-17 | 2019-11-15 | 弗雷德哈钦森癌症研究中心 | 用于治疗bcma相关癌症和自身免疫性失调的联合疗法 |
| KR102845789B1 (ko) | 2017-11-01 | 2025-08-14 | 주노 쎄러퓨티크스 인코퍼레이티드 | B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드 |
| US12193994B2 (en) * | 2017-11-06 | 2025-01-14 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
| AU2019266150A1 (en) * | 2018-05-06 | 2021-01-07 | Ayala Pharmaceuticals Inc. | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof |
| EP3860562A1 (en) | 2018-10-02 | 2021-08-11 | Frequency Therapeutics, Inc. | Pharmaceutical compositions comprising otic therapeutic agents and related methods |
| SG11202111191YA (en) | 2019-04-08 | 2021-11-29 | Frequency Therapeutics Inc | Combination of chir99021 and valproic acid for treating hearing loss |
| US11999750B2 (en) | 2022-01-12 | 2024-06-04 | Denali Therapeutics Inc. | Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP970705A2 (en) * | 1996-12-23 | 1998-10-31 | Warren J. Porter | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING "beta" -AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS |
| JP2002518481A (ja) | 1998-06-22 | 2002-06-25 | エラン ファーマシューティカルズ，インコーポレイテッド | β−アミロイドペプチドの放出および／またはその合成を阻害するための化合物 |
| CA2325389A1 (en) * | 1998-06-22 | 1999-12-29 | James E. Audia | Compounds for inhibiting beta-amyloid peptide release and/or its synthesis |
| HRP20050663A2 (en) | 2003-02-04 | 2006-12-31 | F. Hoffmann - La Roche Ag | Malonamide derivatives as gamma-secretase inhibitors |
| AU2004270361B2 (en) | 2003-09-09 | 2009-06-25 | F. Hoffmann-La Roche Ag | Malonamide derivatives blocking the activity of gama-secretase |
| WO2005040126A1 (en) | 2003-10-06 | 2005-05-06 | F. Hoffman-La Roche Ag | Substituted dibenzo-azepine and benzo-diazepine derivatives useful as gamma-secretase inhibitors |
| KR101169628B1 (ko) | 2006-03-27 | 2012-07-30 | 에프. 호프만-라 로슈 아게 | 감마 세크레테아제 저해제로서의 말론아미드 유도체 |
| WO2008092786A1 (en) * | 2007-02-02 | 2008-08-07 | F. Hoffmann-La Roche Ag | 6-oxo-6,7-dihydro-5h-dibenzo[b,d]azepin-7-yl derivatives |
| KR20100101624A (ko) | 2008-01-11 | 2010-09-17 | 에프. 호프만-라 로슈 아게 | 암 치료를 위한 감마-세크레타제 저해제의 용도 |
| WO2011060051A1 (en) * | 2009-11-12 | 2011-05-19 | University Of Massachusetts | Methods for treating glioblastoma |
-
2012
- 2012-07-10 JO JOP/2012/0190A patent/JO3148B1/ar active
- 2012-07-10 AR ARP120102486A patent/AR087107A1/es not_active Application Discontinuation
- 2012-07-13 TW TW101125459A patent/TWI568730B/zh active
- 2012-07-18 ES ES12741192.4T patent/ES2544937T3/es active Active
- 2012-07-18 BR BR112014001600-3A patent/BR112014001600B1/pt active IP Right Grant
- 2012-07-18 PE PE2014000129A patent/PE20141061A1/es active IP Right Grant
- 2012-07-18 EA EA201490161A patent/EA023044B1/ru not_active IP Right Cessation
- 2012-07-18 ME MEP-2015-105A patent/ME02171B/me unknown
- 2012-07-18 HR HRP20150771TT patent/HRP20150771T1/hr unknown
- 2012-07-18 EP EP12741192.4A patent/EP2736920B1/en active Active
- 2012-07-18 CA CA2841178A patent/CA2841178C/en active Active
- 2012-07-18 PH PH1/2014/500215A patent/PH12014500215B1/en unknown
- 2012-07-18 US US13/551,681 patent/US8569286B2/en active Active
- 2012-07-18 PT PT127411924T patent/PT2736920E/pt unknown
- 2012-07-18 CN CN201280037471.9A patent/CN103732612B/zh active Active
- 2012-07-18 JP JP2014522877A patent/JP6027110B2/ja active Active
- 2012-07-18 RS RS20150496A patent/RS54135B1/sr unknown
- 2012-07-18 HU HUE12741192A patent/HUE027534T2/en unknown
- 2012-07-18 WO PCT/US2012/047100 patent/WO2013016081A1/en not_active Ceased
- 2012-07-18 KR KR1020147001731A patent/KR101578309B1/ko active Active
- 2012-07-18 MX MX2014001084A patent/MX356536B/es active IP Right Grant
- 2012-07-18 MY MYPI2014700183A patent/MY184303A/en unknown
- 2012-07-18 DK DK12741192.4T patent/DK2736920T3/en active
- 2012-07-18 AU AU2012287251A patent/AU2012287251B2/en not_active Ceased
- 2012-07-18 SI SI201230246T patent/SI2736920T1/sl unknown
- 2012-07-18 AP AP2014007362A patent/AP4080A/en active
- 2012-07-18 PL PL12741192T patent/PL2736920T3/pl unknown
-
2013
- 2013-12-17 IL IL229988A patent/IL229988A/en active IP Right Grant
-
2014
- 2014-01-22 DO DO2014000011A patent/DOP2014000011A/es unknown
- 2014-01-22 MA MA36712A patent/MA35611B1/fr unknown
- 2014-01-23 CL CL2014000175A patent/CL2014000175A1/es unknown
- 2014-01-24 GT GT201400012A patent/GT201400012A/es unknown
- 2014-01-24 CO CO14014585A patent/CO6862159A2/es active IP Right Grant
- 2014-01-24 CR CR20140036A patent/CR20140036A/es unknown
- 2014-01-27 EC ECSP14013179 patent/ECSP14013179A/es unknown
-
2015
- 2015-08-25 CY CY20151100742T patent/CY1116645T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02171B (me) | Spoj za inhibiciju notch signalnog puta | |
| JP2014527042A5 (me) | ||
| HRP20231163T1 (hr) | Prolijekovi glutaminskih analoga | |
| ME02805B (me) | Inhibitori cdc7 | |
| JP2014502638A5 (me) | ||
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| HRP20210681T1 (hr) | Kristalne soli (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroizokinolin-2(1h)-il)-2-hidroksipropil)pirimidin-4-karboksamida | |
| HRP20150952T1 (hr) | Određeni triazolopirazini, njihovi pripravci i postupci njihove upotrebe | |
| EP4356736A3 (en) | Synthesis of boronate salts | |
| PH12019500830A1 (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| JP2017519027A5 (me) | ||
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| HRP20160387T1 (hr) | Spojeni biciklični 2,4-diaminopirimidin derivat kao dualni alk i fak inhibitor | |
| JP2011126896A5 (me) | ||
| ME02800B (me) | Nova triciklična jedinjenja | |
| HRP20171895T1 (hr) | Hemisulfatna sol 5,10-metilen-(6r)-tetrahidrofolne kiseline | |
| MX2014009757A (es) | Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia. | |
| HRP20210319T1 (hr) | Kombinacije inhibitora fgfr i inhibitora igf1r | |
| HRP20160545T1 (hr) | Inhibitor fosfoinozitid 3-kinaze sa dijelom koji veže cink | |
| JP2016528242A5 (me) | ||
| JP2015519396A5 (me) | ||
| JP2015507020A5 (me) | ||
| ZA200807323B (en) | Use of CK2 inhibitor for the treatment and chemosensibilization of refractory tumors to anticancer drugs | |
| HRP20220358T1 (hr) | Nove soli nilotiniba i njihovi polimorfi |